R2P -> RP
Phase 2Small molecule
R2P -> RP is one of 18 small molecule programs targeting Lenalidomide. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Lenalidomide
#DrugCompanyPhaseTrials
1Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Rituxan
RochePhase 3
Decadron
AAspen Global Incorporated
Phase 3
Gazyva
RochePhase 2
Oncovin
Eli LillyPhase 2
Adriamycin
PfizerPhase 2
Trexall
Jazz PharmaceuticalsPhase 2
Calquence
AstraZenecaPhase 2
Belamaf
GSKPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R2P -> RP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNOBO Medicine